SFYB.SG - Synthetic Biologics Inc. Regist

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.176
+0.001 (+0.57%)
At close: 5:13PM CEST
Stock chart is not supported by your current browser
Previous Close0.175
Open0.169
Bid0.000 x 500000
Ask0.000 x 500000
Day's Range0.169 - 0.176
52 Week Range0.157 - 0.875
Volume0
Avg. Volume65
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE29 days ago

    Stock Performance Review on Sesen Bio and Three Other Biotech

    LONDON, UK / ACCESSWIRE / June 20, 2018 / If you want a free Stock Review on SESN sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American
    PR Newswire2 months ago

    Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American

    ROCKVILLE, Md., May 22, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, announced today that the NYSE American LLC (the "Exchange") has accepted the Company's plan of compliance (the "Plan") for continued listing on the Exchange. As previously reported, on March 2, 2018, Synthetic Biologics received a letter from NYSE American Staff indicating that the Company is not in compliance with certain continued listing standards relating to stockholders equity as set forth in Part 10, Section 1003 of the NYSE American Company Guide (the "Guide"). Based on the Company's 2017 annual report on Form 10-K, the Company is below compliance with Part 10, Section 1003(a)(iii) of the Guide since it reported stockholders' equity of less than $6 million and net losses in five of its most recent fiscal years as of December 31, 2017.

  • ACCESSWIRE2 months ago

    Stock Performance Review on Tesaro and Three Other Biotech Industry

    LONDON, UK / ACCESSWIRE / May 21, 2018 / If you want a free Stock Review on TSRO sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Surface Oncology Inc. (SURF), Synthetic Biologics Inc. (NYSE AMER: SYN), Teligent Inc. (NASDAQ: TLGT), Tesaro Inc. (NASDAQ: TSRO).

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SYN earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 Synthetic Biologics Inc Earnings Call

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Crown, American Equity Investment Life Holding, Acco Brands, Synthetic Biologics, Universal Display, and Lamb Weston — Future Expectations, Projections Moving into 2018

    NEW YORK, May 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Crown ...

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 8) CONMED Corporation (NASDAQ: CNMD ) Enanta Pharmaceuticals Inc ...

  • Associated Press2 months ago

    Synthetic Biologics: 1Q Earnings Snapshot

    The Rockville, Maryland-based company said it had a loss of 2 cents per share. The company's shares closed at 25 cents. A year ago, they were trading at 46 cents. _____ This story was generated by Automated ...

  • Synthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results
    PR Newswire2 months ago

    Synthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results

    -- Preliminary Agreement Reached with FDA on Proposed Phase 3 Clinical Trial Synopsis for SYN-004 (ribaxamase) -- -- Conference Call Today, May 8, 2018, at 4:30 p.m. (EDT) -- ROCKVILLE, Md. , May 8, 2018 ...

  • Synthetic Biologics to Report First Quarter 2018 Operational Highlights and Financial Results on May 8, 2018
    PR Newswire3 months ago

    Synthetic Biologics to Report First Quarter 2018 Operational Highlights and Financial Results on May 8, 2018

    -- Conference Call Scheduled for Tuesday, May 8, 2018 at 4:30 p.m. EDT -- ROCKVILLE, Md. , April 26, 2018 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...

  • Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection
    PR Newswire3 months ago

    Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection

    ROCKVILLE, Md., April 23, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has preliminary agreement from the U.S. Food & Drug Administration (FDA), on a proposed clinical trial synopsis for its planned Phase 3 clinical trial for SYN-004 (ribaxamase). In accordance with recommendations and guidance received from the FDA, the Company expects the Phase 3 trial to include separate co-primary endpoints designed to evaluate the efficacy and safety of ribaxamase in a patient population being treated with a representative selection of intravenous (IV) beta-lactam antibiotics.

  • Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
    PR Newswire4 months ago

    Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan

    ROCKVILLE, Md., March 7, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced it has received written communication from NYSE American LLC (the "Exchange"), the Company's current listing exchange, stating that it is not in compliance with certain continued listing standards as set forth in the NYSE American Company Guide. In order to maintain its listing, the Company intends to submit a plan of compliance by April 3, 2018 addressing how it intends to regain compliance with certain Exchange continued listing standards by September 2, 2019. If the plan is accepted, the Company may be able to continue its listing but will be subject to periodic reviews by the Exchange.

  • Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results
    PR Newswire5 months ago

    Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results

    -- Company Provides Update on Late-stage Microbiome-focused Product Candidates -- -- Conference Call Today, February 22, 2018, at 8:30 a.m. (EST) -- ROCKVILLE, Md. , Feb. 22, 2018 /PRNewswire/ --  Synthetic ...

  • ACCESSWIRE5 months ago

    Synthetic Biologics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Synthetic Biologics, Inc. (NYSE: SYN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018 at 8:30 AM Eastern ...

  • Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018
    PR Newswire5 months ago

    Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018

    -- Conference Call Scheduled for Thursday, February 22, 2018 at 8:30 a.m. EST -- ROCKVILLE, Md. , Feb. 15, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...

  • Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference
    PR Newswire6 months ago

    Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference

    ROCKVILLE, Md. , Jan. 2, 2018 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore ...

  • Synthetic Biologics Announces Management Changes
    PR Newswire7 months ago

    Synthetic Biologics Announces Management Changes

    ROCKVILLE, Md., Dec. 5, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steve Shallcross, the Company's Chief Financial Officer, has been named interim CEO to succeed Jeff Riley, who has resigned as an officer and director of the Company, effective immediately, for personal reasons. Jeffrey Kraws, the Company's non-executive Independent Chairman of the Board stated, "The Board is very confident in the ability of Steve Shallcross and Joe Sliman, the Company's Chief Medical Officer, to continue the Company's development activities.

  • CNW Group8 months ago

    ImmunoPrecise Realigns Senior Management

    ImmunoPrecise Realigns Senior Management

  • Associated Press9 months ago

    Synthetic Biologics reports 3Q loss

    The Rockville, Maryland-based company said it had a loss of 14 cents per share. In the final minutes of trading on Wednesday, the company's shares hit 78 cents. A year ago, they were trading at $1.31. ...

  • Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results
    PR Newswire9 months ago

    Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results

    -- Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs -- -- Held Initial Type-B Multidisciplinary Meeting with FDA to Discuss Late-Stage Clinical Advancement for ...

  • Synthetic Biologics to Report Third Quarter 2017 Operational Highlights and Financial Results on November 1, 2017
    PR Newswire9 months ago

    Synthetic Biologics to Report Third Quarter 2017 Operational Highlights and Financial Results on November 1, 2017

    -- Conference Call Scheduled for Wednesday, November 1, 2017 at 4:30 p.m. EDT -- ROCKVILLE, Md. , Oct. 25, 2017 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...

  • ACCESSWIRE10 months ago

    Today's Research Reports on Stocks to Watch: Synthetic Biologics and Microbot Medical

    NEW YORK, NY / ACCESSWIRE / September 18, 2017 / Shares of both Synthetic Biologics and Microbot Medical soared this past Friday after the companies had exciting news to share with investors. Synthetic ...

  • Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
    PR Newswire10 months ago

    Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing

    ROCKVILLE, Md., Sept. 12, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today the closing of a privately placed stock purchase transaction for the sale of redeemable convertible preferred stock to an affiliate of MSD Partners, L.P. for aggregate gross proceeds of $12 million. Synthetic Biologics intends to use proceeds from the Preferred Stock transaction for general corporate purposes, including the continued advancement of SYN-004 (ribaxamase), the Company's Breakthrough Therapy Designation drug candidate designed to prevent antibiotic-mediated C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR) in the gut microbiome.

  • ACCESSWIRE10 months ago

    Synthetic Biologics, Inc. Provides Company Overview and Update on Clinical Development in New SNNLive Video Interview with StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / September 6, 2017 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Jeff Riley, CEO of Synthetic Biologics, Inc. (NYSE ...